| Literature DB >> 29439283 |
Theoni Kanellopoulou1, Efrosyni Nomikou2.
Abstract
There are only a few cases of patients with hemophilia A and B who have undergone coronary artery bypass surgery. High levels of replacement therapy with factor concentrate either with bolus or continuous infusion are usually required pre-operatively and during the first post-operative days in order to maintain the coagulation deficient factor levels greater than 80% of normal. Heparinization during cardiopulmonary bypass appears to be safe and intra-operative blood salvage using cell saver techniques reduce the need for transfusions.Entities:
Keywords: cardiac surgery; coronary artery bypass; factor concentrate; hemophilia; ischemic heart disease; replacement therapy
Mesh:
Substances:
Year: 2018 PMID: 29439283 DOI: 10.1111/jocs.13530
Source DB: PubMed Journal: J Card Surg ISSN: 0886-0440 Impact factor: 1.620